The kynurenine pathway in patients with rheumatoid arthritis during tumor necrosis factor α inhibitors treatment [PDF]
RheumatologyObjectives The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis (RA).
Joanna Witoszyńska-Sobkowiak +5 more
doaj +2 more sources
Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence [PDF]
Gut and Liver, 2022 Background/Aims: Many patients with Crohn’s disease (CD) undergo intestinal resection during the disease course. Despite surgery, postoperative recurrence (POR) commonly occurs.
Jongwook Yu +8 more
doaj +2 more sources
Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. [PDF]
PLoS ONEBackgroundPatients with inflammatory bowel disease may develop infective pneumonia after using tumor necrosis factor-α inhibitors(TNFis). Due to the limitations of clinical trials, the occurrence of infective pneumonia in patients with inflammatory bowel
Qinhui Tang +4 more
doaj +2 more sources
Spirohypertones A and B as potent antipsoriatics: Tumor necrosis factor-α inhibitors with unprecedented chemical architectures [PDF]
Acta Pharmaceutica Sinica BTumor necrosis factor-α (TNF-α) is a promising target for inflammatory and autoimmune diseases. Spirohypertones A (1) and B (2), two unprecedented polycyclic polyprenylated acylphloroglucinols with highly rearranged skeletons, were isolated from ...
Yulin Duan +9 more
doaj +2 more sources
Development of Crohn´s disease in a patient with ankylosing spondylitis and essential thrombocythemia folowing etanercept therapy: A case report and review of the literature [PDF]
Vojnosanitetski Pregled, 2021 Introduction. The development of inflammatory bowel disease during the treatment with tumor necrosis factor-α inhibitors is seen in patients with ankylosing spondylitis. Crohn´s disease is the mainly developing form, and etanercept is the most frequently
Milić Biljana +5 more
doaj +1 more source
Use of inhibitors of tumor necrosis factor α in women with ankylosing spondylitis
Современная ревматология, 2021 Objective: to present our own experience of tumor necrosis factor α (TNFα) inhibitors (iTNFα) usage during pregnancy in women with ankylosing spondylitis (AS), to assess AS activity and outcomes of gestation.Patients and methods.
O. A. Krichevskaya +4 more
doaj +1 more source
The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19
Современная ревматология, 2021 The review highlights the problem of finding new effective treatment strategies for COVID-19. Tumor necrosis factor α (TNF-α) is considered as a therapeutic target.
E. S. Aronova, B. S. Belov
doaj +1 more source
Biological treatment of psoriasis [PDF]
Farmacja Polska, 2022 Psoriasis is the most common, inflammatory, chronic skin disease, with possible systemic manifestations. It affects about 2-3% of the population and is equally common in women and men.
Sylwia Słuczanowska-Głąbowska +6 more
doaj +1 more source
Vasculitis Associated With Tumor Necrosis Factor-α Inhibitors [PDF]
Mayo Clinic Proceedings, 2012 Olayemi Sokumbi +2 more
exaly +2 more sources
Tumor necrosis factor-? inhibitors in therapy for psoriatic arthritis
Современная ревматология, 2010 The paper presents the data available in the literature on the efficacy and tolerability of basic tumor necrosis factor α inhibitors (TNF α) etanercept, adalimumab, infliximab in the treatment of psoriatic arthritis (PsA) and their effects on the major ...
Vladimir Vasilyevich Badokin +2 more
doaj +3 more sources